Nurix Therapeutics, Inc. 4

CSO Gwenn Hansen had several RSU tranches vest into Nurix Therapeutics common stock and sold 3,847 shares in a mandated sell-to-cover trade for taxes, ending with 121,338 directly owned shares plus significant remaining RSU holdings.

On July 30, 2026, Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen had multiple RSU tranches vest and convert into common stock (3,750, 2,858, and 3,572 shares at $0 per share), increasing her directly held common stock to 125,185 shares. In connection with this vesting, she executed a mandatory sell-to-cover transaction of 3,847 shares of common stock at a weighted average price of $23.3828 (within a $23.00–$23.90 range) solely to satisfy tax withholding obligations under the company’s equity incentive plan, reducing her post-sale direct holdings to 121,338 shares. After these transactions, she also continued to hold unvested restricted stock units (11,250, 20,009, and 39,303 RSUs in three separate awards), each representing a contingent right to receive one share of common stock, vesting quarterly over three years with no exercise price and no expiration other than vesting or cancellation.

Filing Facts

CIK

1549595

Ticker

NRIX

Form

4

Source Type

fda

Accession

0001817160-26-000012

Alert Tier

5